Work

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Year: 2018

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-17-3436

Authors: Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas

Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Seattle Cancer Care Alliance, Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, University of California, Los Angeles, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2792949427

FWCI: 2.863

Cites: 41

Cited by: 57

Related to: 10